{"denoms":[{"counts":[{"groupId":"BG000","value":"383"},{"groupId":"BG001","value":"387"},{"groupId":"BG002","value":"770"}],"units":"Participants"}],"groups":[{"description":"Participants were treated with irinotecan liposome injection 50 mg/m\\^2 followed by oxaliplatin 60 mg/m\\^2, followed by LV 400 mg/m\\^2 and then 5-FU 2400 mg/m\\^2 IV infusion on Days 1 and 15 of each 28-day cycle until disease progression, death, unacceptable study treatment-related toxicity or withdrawal of consent.","id":"BG000","title":"NALIRIFOX"},{"description":"Participants were treated with nab-paclitaxel 125 mg/m\\^2 followed by gemcitabine 1000 mg/m\\^2 IV on Days 1, 8 and 15 of each 28-day cycle until disease progression, death, unacceptable study treatment-related toxicity or withdrawal of consent.","id":"BG001","title":"Nab-paclitaxel+Gemcitabine"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.71","value":"62.8"},{"groupId":"BG001","spread":"8.34","value":"64.0"},{"groupId":"BG002","spread":"9.06","value":"63.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"179"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"336"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"204"},{"groupId":"BG001","value":"230"},{"groupId":"BG002","value":"434"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"79"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"305"},{"groupId":"BG001","value":"328"},{"groupId":"BG002","value":"633"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"58"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"324"},{"groupId":"BG002","value":"639"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"55"}]}],"title":"Not Reported"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"38"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"19"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}],"title":"Multiple"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Native Hawaiian or Other Pacific Islander"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The Intent-to-Treat (ITT) population consisted of all randomized participants to whom study treatment was assigned by randomization."}